Clinical trials: Caesarean Section
Cervical Ripening, Induction of Labor
Pharmacokinetic (PK) Study of the 200 Microgram (mcg) Misoprostol Vaginal Insert (MVI 200) in Women at Term Gestation (The MVI-PK Study)
The purpose of this study is to determine the pharmacokinetics (PK) of misoprostol acid for the MVI 200 in women requiring cervical ripening and induction of labor.
- Trial name
- NCT01283022
- Testing
- MVI 200
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ferring Pharmaceuticals
Cervical Ripening, Induction of Labor
Misoprostol Vaginal Insert (MVI) 100, 150, 200 mcg for Cervical Ripening and Induction of Labor
The purpose of this study is to assess the efficacy and safety of the 100, 150 and 200 mcg Misoprostol Vaginal Insert (MVI 100, MVI 150 and MVI 200) for women requiring cervical ripening and induction of labor.
- Trial name
- NCT00828711
- Testing
- MVI 100, MVI 150, MVI 200
- Where
- 11 sites in United States
- Volunteers
- 374 people
- Sponsor
- Ferring Pharmaceuticals
Pain
Evaluation of the Safety and Efficacy of EXPAREL When Administered Into the TAP in Subjects Undergoing Cesarean Section
This is a Phase 4, multicenter, open-label study evaluating EXPAREL infiltration into the transversus abdominis plane (TAP) after bupivacaine hydrochloride (HCl) spinal anesthesia in subjects undergoing elective Cesarean section…
- Trial name
- NCT02353754
- Testing
- Intrathecal morphine injection, EXPAREL
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Post-operative Complications, Surgical Site Infection
The Use of the Prevena™ Incision Management System on Post-Surgical Cesarean Section Incisions
The purpose of this study is to compare the post-surgical standard-of-care dressing to the Prevena™ Incision Management System in women undergoing Cesarean section surgery.
- Conditions
- Post-operative Complications, Surgical Site Infection, Surgical Wound Infection
- Trial name
- NCT01450631
- Testing
- Prevena™ Incision Management System (PIMS), Standard-of-care Dressing
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- KCI USA, Inc
Elective Cesarean Section, Pain Management
Efficacy and Safety of EXPAREL Versus Standard of Care (SoC) in Subjects Undergoing Elective Cesarean Section
The purpose of this study is to compare total opioid consumption by subjects in different treatment groups. Another purpose of this study is to assess how well EXPAREL works, collect any safety data and assess your satisfaction…
- Trial name
- CHOICE (NCT03853694)
- Testing
- 50 mcg Duramorph+ EXPAREL + multi-modal pain regimen, 150 mcg Duramorph + multi-modal pain regimen, Exparel TAP + multi-modal pain regimen
- Where
- 18 sites in United States
- Volunteers
- 167 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Unplanned Caesarean Section
Chloroprocaine 3% - Epidural Anesthesia in Unplanned Caesarean Section
The study evaluate the quality of epidural anaesthesia and the safety of Chloroprocaine HCl 3% compared with Ropivacaine HCl 0.75% in patients with an epidural catheter in situ undergoing unplanned Caesarean section.
- Trial name
- NCT02919072
- Testing
- Chloroprocaine, Ropivacaine
- Where
- Belgium
- Volunteers
- 16 people
- Sponsor
- Sintetica SA
C-Section, Pain Management
Evaluate the Safety and Efficacy of EXPAREL When Administered Via Infiltration Into the TAP vs. Bupivacaine Alone in Subjects Undergoing Elective C-Sections
Primary objective: The primary objective of this study is to compare total opioid consumption through 72 hours following EXPAREL+bupivacaine HCl infiltration into the transversus abdominis plane (TAP) after spinal anesthesia to…
- Trial name
- C-Section (NCT03176459)
- Testing
- Exparel + Bupivacaine, Bupivacaine
- Where
- 12 sites in United States
- Volunteers
- 186 people, healthy volunteers welcome
- Sponsor
- Pacira Pharmaceuticals, Inc
Reducing Time to Vaginal Delivery, Cervical Ripening
Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery
The purpose of this study is to determine whether the Misoprostol Vaginal Insert (MVI) 200 microgram (mcg) can decrease the time to vaginal delivery compared to the Dinoprostone Vaginal Insert (DVI) 10 milligram (mg) in pregnant…
- Conditions
- Reducing Time to Vaginal Delivery, Cervical Ripening, Induction of Labor
- Trial name
- EXPEDITE (NCT01127581)
- Testing
- MVI 200, Dinoprostone Vaginal Insert (DVI)
- Where
- 34 sites in United States
- Volunteers
- 1,358 people
- Sponsor
- Ferring Pharmaceuticals
Cervical Ripening, Labor, Induced
Safety/Efficacy Study Comparing the Misoprostol Vaginal Insert to Cervidil for Cervical Ripening and Induction of Labor
The purpose of this study is to determine whether the misoprostol vaginal insert (50 mcg and 100 mcg) can safely and effectively speed time to vaginal delivery compared to Cervidil (R) in women who need to have cervical ripneing…
- Trial name
- NCT00308711
- Testing
- Misoprostol vaginal insert 100 mcg, Misoprostol vaginal insert 50 mcg, Dinoprostone vaginal insert (Cervidil)
- Where
- 52 sites in United States, Canada
- Volunteers
- 1,308 people
- Sponsor
- Ferring Pharmaceuticals
Cesarean Section Complications, Post Partum Hemorrhage
DAISY Uterine Drain Device Evaluation
The goal of this study is to obtain user feedback while placing and observing the DAISY uterine drain with wall suction. This study defines the obstetrical surgeons as "users" and the patients in whom the drain is placed as…
- Conditions
- Cesarean Section Complications, Post Partum Hemorrhage, Uterine Atony With Hemorrhage, Uterine Bleeding
- Trial name
- NCT06219538
- Testing
- DAISY Uterine Drain
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Raydiant Oximetry, Inc.